Megan Ji

Cooley advised AN2 Therapeutics on its $79 million initial public offering of 4,600,000 shares of common stock at a price to the public of $15.00 per share. AN2 is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Partner Josh Seidenfeld, associate Anitha Anne and Sally Kay of counsel led the Cooley team.

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.

Cooley advised Dynavax Technologies on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. Dynavax Technologies, whose securities trade on the Nasdaq Capital Market under the symbol DVAX, is a biopharmaceutical company focused on developing and commercializing novel vaccines. Partners Steve Przesmicki, Mischi a Marca and Jason Savich le the Cooley team.